Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment
Autor
Olloquequi, Jordi
Ettcheto, Miren
Cano, Amanda
Fortuna, Ana
Bicker, Joana
Sánchez-Lopez, Elena
Paz, Cristian
Ureña, Jesús
Verdaguer, Ester
Auladell, Carme
Camins, Antoni
Resumen
Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A’s effects on the central nervous system and its potential application in Alzheimer’s disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential. © 2023 by the authors.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease (2024)
Olloquequi, Jordi; Ettcheto, Miren; Cano, Amanda; Sanchez-López, Elena; Carrasco, Marina; Espinosa, Triana; Beas-Zarate, Carlos; Gudiño-Cabrera, Graciela; Ureña-Guerrero, Monica E.; Verdaguer, Ester; ... (Bioscience Research Institute, 2022)The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer’s disease (AD) being the most common cause. In spite of decades of intensive research, no cure ... -
Article
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet (2024)
Espinosa-Jiménez, Triana; Cano, Amanda; Sánchez-López, Elena; Olloquequi, Jordi; Folch, Jaume; Bulló, Mònica; Verdaguer, Ester; Auladell, Carme; Pont, Caterina; Muñoz-Torrero, Diego; ... (BioMed Central Ltd, 2023)Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the global burden of AD and the advances made in AD drug research and development, the cure of the disease remains elusive, since ... -
Article
Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders (2024)
Olloquequi, Jordi; Cano, Amanda; Sanchez-López, Elena; Carrasco, Marina; Verdaguer, Ester; Fortuna, Ana; Folch, Jaume; Bulló, Mònica; Auladell, Carme; Camins, Antoni; ... (Elsevier Masson s.r.l., 2022)Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been ...